乙肝病毒X基因真核表达质粒及细胞模型的建立

采用聚合酶链反应（PCR）方法扩增HBVX基因,定向亚克隆入真核表达载体pRc／CMV2．构建重组质粒pCMV／X;采用脂质体法转染QSG7701细胞,筛选阳性细胞克隆;RT—PCR法检测HBV XmRNA的表达情况．Western blotting法鉴定HBx蛋白的表达,结果表明,构建的真核重组表达质粒pCMV／X中包含有完整的HBVX基因片断,pCMV／工转染的QSG7701细胞中有HBVXmRNA及HBx蛋白的稳定表达．成功建立了HBVX稳定转染的细胞系,为进一步探讨HBx在HCC的发生发展过程中所起的作用,提供了一个有价值的细胞模型．     

ω-3多聚不饱和脂肪酸脱氢酶的真核表达及鉴定

目的：构建ω-3多聚不饱和脂肪酸脱氢酶真核表达载体,并在293T细胞（人胚肾细胞）中实现表达。方法：通过RT-PCR法扩增得到ω-3多聚不饱和脂肪酸脱氢酶基因fat1,构建重组真核表达载体pCMV－Myc－fat1,用脂质体法转染293T细胞,Western Blot检测fat1的表达,并用间接免疫荧光（IFA）确定其在293T细胞中的定位情况。结果：构建真核表达质粒pCMV－Myc－fat1,转染293T细胞后,可检测到细胞内有fat1的表达并确定其在细胞中的位置。结论：成功构建真核表达质粒pCMV－Myc－fat1,可检测出细胞内有fat1的表达并确定其在细胞膜和细胞质内均有表达,为进行fat1的功能研究奠定了基础。     

人sTNFR1基因的克隆以及在NIH3T3细胞中的稳定表达

以He1a细胞的总RNA为模板,用RT—PCR方法扩增sTNFR1全编码区基因片段,构建含有目的片段的T载体克隆及真核表达载体pcDNA3．1（-）重组质粒亚克隆,将重组质粒和脂质体共同转染NIH3T3细胞系,G418筛选稳定转染细胞株．经核苷酸序列测序和酶切鉴定,成功构建了pcDNA3．1（-）-sTNFR1真核表达质粒,脂质体法建立了高效表达sTNFRI的稳定转染细胞系,并经RT—PCR和Western Blotting鉴定．人sTNFR1基因能在NIH3T3细胞系中稳定表达,为今后的研究打下了基础．     

Smad4基因siRNA表达载体的构建与鉴定

目的:以Smad4基因为靶标构建小干扰RNA(siRNA)真核表达载体.方法:根据GenBank公布的人Smad4核酸序列及SiRNA设计原则,用AmbionRNAi在线软件,筛选得到2个19 bp片段为靶序列,合成两端带有Bam H Ⅰ、HindⅢ酶切位点的发夹结构寡核苷酸序列,经过退火,将此序列克隆到真核表达质粒pSilencerTM3.1-H1 neo vector中,构建成重组质粒,酶切及测序验证.脂质体介导转染人原代增生性瘢痕成纤维细胞,经G418筛选细胞克隆,并用RT-PCR检测Smad4基因的表达.结果:成功构建了pSilencerTM3.1.H1 neo-Smad4 shRNA表达载体克隆,插入片段测序结果与合成的siRNA序列一致.RT-PCR结果显示转染shRNA1、shRNA2重组质粒的成纤维细胞内Smad4 mRNA水平均降低,其中以pSilencerTM3.1-H1-Smad4 shRNA1更为明显(P＜0.01).结论:构建P-Smad4 shRNA袁达载体成功,为进一步研究Smad4基因的RNA干扰奠定了基础.     

人RhoB基因真核表达载体的构建和表达分析

旨在构建带Flag标签的人RhoB基因真核表达载体并检测其表达。提取人胚肾细胞HEK-293T总RNA并反转录获得cDNA;设计引物并利用PCR技术扩增RhoB基因的ORF序列;将所扩增序列插入到带Flag标签的pCMV5真核表达载体,插入位点位于限制性内切酶SalⅠ和XbaⅠ之间,得到真核表达载体Flag-RhoB。酶切并测序验证该质粒的准确性。将成功构建的Flag-RhoB质粒转染乳腺癌MCF7细胞、宫颈癌HeLa细胞以及结直肠癌HCT116细胞,Western Blotting检测RhoB蛋白的表达情况;转染Mv.1.Lu细胞,免疫荧光技术检测该蛋白在细胞中的定位情况。成功扩增出RhoB基因的ORF序列;连入pCMV5中获得真核表达质粒Flag-RhoB;酶切鉴定得到590 bp大小的片段,测序结果显示连入的是RhoB基因的cDNA序列与GenBank相符。Western Blotting结果显示,该质粒可在MCF7细胞、HeLa细胞及HCT116细胞中正确表达。免疫荧光实验显示过表达的RhoB蛋白主要定位于细胞膜上,细胞质中也有分布。成功构建了带Flag标签的人RhoB基因的真核表达载体,该质粒可在细胞中顺利表达。     

猪卵透明带ZP3α真核表达载体的构建及体外瞬时表达

目的：构建猪卵透明带zP3α真核表达栽体,为探讨卵透明带DNA疫苗避孕疫苗奠定基础。方法：采用PCR法获得了去除N端信号肽序列和C端跨膜区序列的猪卵透明带ZP3α的cDNA序列片段,以专门用于发展DNA疫苗的质粒pVAX1为载体构建了真核细胞表达质粒pvAX1-pZP3α。通过脂质体转染将之导入HeLa细胞进行体外瞬时表达,然后采用RT—PGR和间接免疫荧光技术(IIF)检测pZP3α在mRNA水平的转录和蛋白质水平上的表达。结果：真核细胞表达质粒pVAX1-pZP3α构建成功,用RT-PCR和IIF技术检测到了pZP3α在HeLa胞中的转录与表达。结论：真核表达载体pVAX1—pzP3aα的成功构建和表达为研制开发有效的人用卵透明带DNA避孕疫苗奠定了基础。     

破伤风毒素C片段基因克隆、重组表达及免疫原性研究

应用PCR技术从破伤风梭状芽孢杆菌DNA中扩增出1．4kbDNA基因,将其克隆到pUC18质粒中,经测序证明该DNA片段为破伤风片段C的基因,并将此基因片段亚克隆到pGEX-4T-2,构建成表达质粒pGEX－TC在E．coli中进行表达。经聚丙烯酰胺凝胶电泳和免疫印迹鉴定,表达产物为76KD的特异性重组蛋白。动物实验显示：1μg重组蛋白免疫动物,可使动物产生1IU／ml的破伤风抗毒素单位,动物血清的抗体滴度可达1：800。     

小鼠DLL1真核表达载体的构建及其在肿瘤细胞中的表达

目的：构建带绿色荧光蛋白的小鼠DLL1全长基因真核表达载体,并在肿瘤细胞中表达。方法：利用PCR特异性引物扩增出DLL1基因全长,将克隆的基因片段插入带绿色荧光蛋白的真核表达载体pIRES2-EGFP质粒中。然后利用脂质体将重组质粒pIRES2-EGFP-DLL1转染进小鼠B16黑色素瘤细胞中,并通过G418筛选后选取生长良好、荧光强度高的三株单克隆进行mRNA水平DLL1表达的鉴定。结果：成功扩增小鼠DLL1的全长基因。克隆入质粒载体后,通过DNA序列测定证实其序列正确。将构建的pIRES2-EGFP-DLL1质粒转染小鼠B16黑色素瘤细胞,经过G418筛选和荧光显微镜观察后,挑选得到GFP阳性率90%以上的稳定转染细胞株。RT-PCR检测稳定转染细胞的mDLL1的表达显著增加,进一步证实了pIRES2-EGFP-DLL1的表达效能。结论：成功构建了小鼠DLL1基因的真核表达质粒,证实其在真核细胞B16中可以表达。     

小鼠DLL1真核表达载体的构建及其在肿瘤细胞中的表达

目的:构建带绿色荧光蛋白的小鼠DLL1全长基因真核表达载体,并在肿瘤细胞中表达。方法:利用PCR特异性引物扩增出DLL1基因全长,将克隆的基因片段插入带绿色荧光蛋白的真核表达载体pIRES2-EGFP质粒中。然后利用脂质体将重组质粒pIRES2-EGFP-DLL1转染进小鼠B16黑色素瘤细胞中,并通过G418筛选后选取生长良好、荧光强度高的三株单克隆进行mRNA水平DLL1表达的鉴定。结果:成功扩增小鼠DLL1的全长基因。克隆入质粒载体后,通过DNA序列测定证实其序列正确。将构建的pIRES2-EGFP-DLL1质粒转染小鼠B16黑色素瘤细胞,经过G418筛选和荧光显微镜观察后,挑选得到GFP阳性率90%以上的稳定转染细胞株。RT-PCR检测稳定转染细胞的mDLL1的表达显著增加,进一步证实了pIRES2-EGFP-DLL1的表达效能。结论:成功构建了小鼠DLL1基因的真核表达质粒,证实其在真核细胞B16中可以表达。     

APC11基因真核表达质粒构建及鉴定

目的克隆扩增APC11开放阅读框基因片段,构建其真核表达重组质粒,为后续研究其功能做准备。方法按照GenBank中人APC11序列设计引物,以HeLa细胞cDNA为模板,扩增出基因片段。该片段与真核表达载体pEGFP-C1连接,得到的重组质粒经双酶切和测序鉴定后用Western印迹检验表达。结果扩增片段长度为285bp,重组真核表达质粒经双酶切鉴定后测序鉴定正确。Western印迹证实pEGFP—C1-APC11在真核细胞内表达。结论成功克隆了APC11基因并构建了pEGFP—C1-APC11真核表达重组质粒,Western印迹证实其表达良好,对该基因功能的深入研究打下了坚实基础。     

日本血吸虫32kDa蛋白质基因在真核表达载体中的亚克隆

设计和合成特定寡核苷酸引物,TRIZOL提取日本血吸虫成虫RNA,RT-PCR法扩增日本血吸虫32kDa蛋白质(Sj32)基因编码序列,将扩增产物连接pGEM-T克隆载体,再亚克隆到真核表达载体pBKCMV中.结果RT-PCR法特异性扩增出Sj32编码基因片段,其大小约为1270bp,经双酶切、PCR鉴定表明所构建的质粒pGEM-Sj32和pBK-Sj32中含有目的基因.pBK-Sj32重组质粒的成功构建,为进一步表达Sj32及其在血吸虫病免疫诊断、免疫预防中的作用研究提供了条件.     

Construction, characterization and expression of full length cDNA clone of sheep YAP1 gene

RT-PCR, 5′RACE, 3′RACE were used to clone sheep full length cDNA sequence of YAP1 (Yes-associated protein 1), eukaryotic expression plasmid and a mutant that cannot be phosphorylated at Ser42 was successfully constructed. The amino acid sequence analysis revealed that sheep YAP1 gene encoded water-soluble protein and its relative molecular weight and isoelectric point was 44,079.0 Da and 4.91, respectively. Sub-cellular localization of YAP1 was in the nucleus, it is hydrophilic non-transmembrane and non-secreted protein. YAP1 protein contained 33 phosphorylation sites, seven glycosylation sites and two WW domains. The secondary structure of YAP1 was mainly composed of random coil, while the tertiary structure of domain area showed a forniciform helix structure. YAP1 gene was expressed in different tissues, the highest expression was in kidney and the lowest was in hypothalamus. The CDS of sheep YAP1was amplified by RT-PCR from healthy sheep longissimus dorsi muscle, cloned into pMD19-T simple vector by T/A ligation. YAP1 coding region was further sub-cloned into pEGFP-C1 vector by T4 Ligase to construct a eukaryotic expression plasmid and then make the eukaryotic expression vector as the template to construct the phosphorylation site mutant. PCR, restriction enzyme and sequencing were used to confirm the recombinant plasmid. The sheep full-length YAP1 cDNA sequence is 1712 in length encoding 403 amino acids. It was confirmed that the sheep YAP1 CDS was correctly inserted into eukaryotic expression vector and serine had been mutated to alanine by PCR, restriction digestion and sequencing. The result showed that the recombinant plasmid pEGFP-C1-YAP1 and pEGFP-C1-YAP1 S42A was constructed correctly, this will help for further studies on the YAP1 protein expression and its biological activities.     

Gene conjugation of molecular adjuvant C3d3 to hCGbeta increased the anti-hCGbeta Th2 and humoral immune response in DNA immunization

Human chorionic gonadotropin (hCG) has been used as an anti-fertility vaccine and as a target for cancer immunotherapy. We have explored the use of three copies of C3d in DNA vaccine as molecular adjuvant to improve the immunogenicity of this hormone in previous work and found that the immune response induced by pcDNA3-hCGbeta-C3d3 has been enhanced 243-fold compared with pcDNA3-hCGbeta following DNA immunization in BALB/c mice. In the present study, a new functionally active DNA vaccine of hCGbeta-C3d3 chimera based on pCMV4 vector has been described. We compared the expression efficiency of pCMV4 and pcDNA3 eukaryotic vectors for hCGbeta and hCGbeta-C3d3 fusion protein and the immune response of mice immunized with pcDNA3-hCGbeta, pCMV4-hCGbeta, pcDNA3-hCGbeta-C3d3 and pCMV4-hCGbeta-C3d3, respectively, at 25, 50 and 100 pmol dose, and further analyzed the levels of Th1 and Th2 cytokines produced by spleen lymphocytes of the immunized mice upon hCG restimulation in vitro. It was found that pCMV4 vector achieved 1.3-1.5-fold higher protein expression and raised 1.1-1.2 (primary) and 1.2-1.3 (booster) logs higher titer of anti-hCGbeta IgG than pcDNA3. Mice vaccinated with 50 pmol of hCGbeta-C3d3-DNAs elicited the highest titer of hCGbeta-specific antibody among the serial doses and the immune response induced by pCMV4-hCGbeta-C3d3 were, respectively, 1.3, 1.3 and 1.2 logs higher than that of pcDNA3-hCGbeta-C3d3 and 2.2, 2.9 and 2.4 logs higher than that of pCMV4-hCGbeta at week 2 following the booster immunization. Moreover, we observed that the production of IL-4 and IL-10 increased in mice vaccinated with hCGbeta-C3d3-DNAs and the ratio of IL-4/IFN-(gamma) showed a Th2 bias of immune response in the mice immunized with hCGbeta-C3d3-DNAs. These findings indicated that gene fusion of C3d3 to hCGbeta, as a means of harnessing the adjuvant potential of the innate immune system, may improve the antigen-specific Th2 humoral immune response of the hCGbeta DNA vaccine and the pCMV4 vector is a more ideal eukaryotic vector for DNA vaccine than pcDNA3.     

促红细胞生成素基因表达载体的构建及其在CHO细胞中表达的研究

用从基因文库中所克隆的促红细胞生成素（ＥＰＯ）基因组基因,构建了３种由不同启动子调控的表达载体——ｐＯＰ１３／ＥＰＯ,ｐＲＳＶ／ＥＰＯ,ｐＣＭＶ／ＥＰＯ,在这３个表达载体的构建过程中对基因的转录起始效率、内含子的剪接、５′非翻译区和３′非翻译区对基因表达的影响等因素都加以考虑．用脂质体转染法分别将上述３个载体导入ＣＨＯ细胞,经瞬时表达,用ＥＬＩＳＡ方法检测,表达量分别为１９０ｍＩＵ／ｍｌ、１６０ｍＩＵ／ｍｌ、４４７ｍＩＵ／ｍｌ．用表达载体ｐＯＰ１３／ＥＰＯ转染ＣＨＯ－Ｋ１２细胞,在４００μｇ／ｍｌ的Ｇ４１８浓度下筛选稳定表达细胞克隆,获得了表达量约为１６０ＩＵ／１０６细胞（４８ｈ）的Ｃ１０细胞株．表达产物经Ｗｅｓｔｅｒｎｂｌｏｔ检测发现了ＥＰＯ阳性条带．用ＴＦ－１细胞对ＥＰＯ进行了生物活性检测,初步证实所表达的ＥＰＯ有生物活性．     

PHD2基因原核表达载体的构建及其在大肠埃希菌中的表达

目的构建PHD2基因原核表达载体pET-43.1b（＋）-PHD2,实现Nus-PHD2融合蛋白在大肠埃希菌中的可溶性表达。方法用SacⅠ酶切pET-43.1b（＋）制备线性化载体,设计与线性化载体两端具有至少15个同源序列的特异性引物,以真核重组质粒pCMV6-Entry-EGLN1为模板,PCR法扩增PHD2目的基因。采用In-Fusion技术构建原核表达载体pET-43.1b（＋）-PHD2,并将其导入大肠埃希菌BL21（DE3）中诱导表达。用SDS-PAGE和Western blot分析并鉴定表达出的融合蛋白。用Ni-NTA亲和层析法纯化目的蛋白。结果成功构建了PHD2原核表达载体;SDS-PAGE结果显示融合蛋白以可溶性形式表达;Western blot鉴定表明融合蛋白可以与PHD2单克隆抗体特异性结合。结论实现了Nus-PHD2融合蛋白在大肠埃希菌中的可溶性表达,为PHD2生物学功能的研究奠定了基础。     

人层粘连蛋白α4链LG3组件的克隆、测序及在原核细胞中的表达

用Trizol法提取胎盘组织总RNA,通过RTPCR方法获得人层粘连蛋白α4链LG3组件的特异扩增产物。将PCR产物克隆入PMD18T载体中,PCR与酶切鉴定正确后进行序列测定。用测序正确的克隆片段与原核表达载体PET28a进行体外重组,构建了LG3的原核表达载体,并在BL21(DE3)菌株中得到了表达。     

兔IFRG基因的克隆及表达分析

实验通过对兔子基因组DNA进行PCR获得兔IFRG基因,将其克隆到pGEM-T载体,双酶切鉴定和测序结果表明成功构建了重组克隆载体pGEM-T-IFRG。通过RT-PCR分析发现IFRG基因在兔不同组织中有不同程度的表达。将重组克隆载体pGEM-T-IFRG和表达载体pET-41（c）经过EcoR1和Xho1双酶切后连接构建重组表达载体pET-41（c）-IFRG,将双酶切鉴定正确的重组表达载体转化入E.coli BL21,IPTG诱导融合蛋白的表达,SDS-PAGE结果显示兔IFRG基因在大肠杆菌中得到了良好的表达。     

猪A组轮状病毒Vp6基因与乳酸菌非抗性表达载体的重组及在大肠杆菌中的表达

以猪A组轮状病毒mRNA为模板,应用反转录聚合酶链式反应(RT-PCR)技术,扩增了1194bp的Vp6基因,通过T-A克隆技术,将PCR产物克隆至克隆载体pGEM-TVector中,构建克隆质粒pGEM-T-Vp6。用SacⅠ和KpnⅠ双酶切pGEM-T-Vp6和以胸苷酸合成酶基因(thymidylate synthase,thyA)为选择压力的非抗生素抗性的穿梭表达载体pW425t,并将纯化的Vp6基因亚克隆至表达载体pW425t中,构建出可以在乳酸菌与大肠杆菌之间穿梭表达的原核表达重组质粒pW425t-Vp6。将pW425t-Vp6转化至thyA基因缺陷型的大肠杆菌感受态E.coliX13中,经生长功能弥补筛选阳性克隆,通过SDS-PAGE分析,可见约44.88kD的融合蛋白。由Western blot分析,表明该蛋白具有与轮状病毒多克隆抗体的反应原性,从而为pW425t-Vp6在乳酸菌受体菌株中表达提供理论基础和实验依据。